MERS
MCID: MDD018
MIFTS: 43

Middle East Respiratory Syndrome (MERS)

Categories: Infectious diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Middle East Respiratory Syndrome

MalaCards integrated aliases for Middle East Respiratory Syndrome:

Name: Middle East Respiratory Syndrome 12 58 15
Mers 58

Classifications:



External Ids:

Disease Ontology 12 DOID:0080642
Orphanet 58 ORPHA576074

Summaries for Middle East Respiratory Syndrome

Disease Ontology : 12 A Coronavirus infection that is characterized by severe respiratory illness, including fever, cough, and shortness of breath and that has material basis in MERS-CoV.

MalaCards based summary : Middle East Respiratory Syndrome, also known as mers, is related to viral pneumonia and avian influenza. An important gene associated with Middle East Respiratory Syndrome is DPP4 (Dipeptidyl Peptidase 4), and among its related pathways/superpathways are NF-kappaB Signaling and Cytosolic sensors of pathogen-associated DNA. The drugs Dexmedetomidine and Heparin have been mentioned in the context of this disorder. Affiliated tissues include t cells, testes and brain, and related phenotype is respiratory system.

Wikipedia : 74 Middle East respiratory syndrome (MERS), also known as camel flu, is a viral respiratory infection... more...

Related Diseases for Middle East Respiratory Syndrome

Diseases related to Middle East Respiratory Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 269)
# Related Disease Score Top Affiliating Genes
1 viral pneumonia 30.7 IFNB1 CXCL10 ACE2
2 avian influenza 30.7 ISG15 FURIN CXCL10
3 ebola hemorrhagic fever 30.7 SCARA3 IFNB1 FURIN
4 vaccinia 30.5 ISG15 IRF3 IFNB1 CEACAM5
5 severe acute respiratory syndrome 30.5 TMPRSS2 IRF3 IFNB1 IFIH1 FURIN CXCL10
6 encephalitis 30.5 PPP1CA IRF3 IFNB1 CXCL10
7 covid-19 30.4 TMPRSS2 FURIN DPP4 CTSL ACE2
8 lassa fever 30.1 SCARA3 IRF3 IFIH1
9 newcastle disease 30.1 IRF3 IFNB1 CXCL10
10 venezuelan equine encephalitis 29.8 PPP1CA IFNB1 CXCL10
11 human immunodeficiency virus type 1 29.7 IRF3 HSPA5 DPP4 CXCL10 ADA
12 influenza 29.6 TMPRSS2 ISG15 IRF3 IFNB1 IFIH1 FURIN
13 immune deficiency disease 29.5 IFNB1 FURIN CXCL10 ADA
14 coronavirus infectious disease 27.8 TMPRSS2 SCARA3 PPP1CA ISG15 IRF3 IFNB1
15 encephalitis/encephalopathy, mild, with reversible myelin vacuolization 11.7
16 respiratory failure 10.5
17 encephalopathy 10.5
18 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.4
19 diarrhea 10.4
20 pneumonia 10.4
21 listeria meningitis 10.4 IFNB1 ADA
22 squamous cell bile duct carcinoma 10.4 DPP4 CEACAM5
23 leukemia, acute lymphoblastic 10.4
24 adult dermatomyositis 10.3 ISG15 IFIH1
25 vulva basal cell carcinoma 10.3 CTSL CEACAM5
26 sting-associated vasculopathy with onset in infancy 10.3 IRF3 IFNB1 IFIH1
27 cutaneous anthrax 10.3 FURIN ADA
28 crimean-congo hemorrhagic fever 10.3 IFNB1 FURIN CXCL10
29 herpangina 10.3 IRF3 IFNB1 IFIH1
30 alk-negative anaplastic large cell lymphoma 10.3 DPP4 ADA
31 tuberculous peritonitis 10.3 CEACAM5 ADA
32 pericardial tuberculosis 10.3 CEACAM5 ADA
33 hantavirus pulmonary syndrome 10.3 IRF3 IFNB1
34 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.3
35 pleural lipoma 10.3 CEACAM5 ADA
36 gastrointestinal tuberculosis 10.2 CEACAM5 ADA
37 pulmonary disease, chronic obstructive 10.2
38 chronic kidney disease 10.2
39 viral encephalitis 10.2 IFNB1 CXCL10 ADA
40 autoimmune disease 10.2
41 marburg hemorrhagic fever 10.2 SCARA3 FURIN
42 abdominal tuberculosis 10.2 CEACAM5 ADA
43 neutropenia 10.2
44 acute kidney failure 10.2
45 measles 10.2
46 microphthalmia with limb anomalies 10.2 ISG15 IRF3 IFNB1 IFIH1
47 primary bacterial infectious disease 10.2 IFNB1 CXCL10 ADA
48 croup 10.2 IFIH1 ACE2
49 systemic lupus erythematosus 10.2
50 glioblastoma multiforme 10.2

Graphical network of the top 20 diseases related to Middle East Respiratory Syndrome:



Diseases related to Middle East Respiratory Syndrome

Symptoms & Phenotypes for Middle East Respiratory Syndrome

MGI Mouse Phenotypes related to Middle East Respiratory Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 respiratory system MP:0005388 9.17 ACE2 ADA DPP4 HSPA5 IRF3 PRKRA

Drugs & Therapeutics for Middle East Respiratory Syndrome

Drugs for Middle East Respiratory Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 177)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
2
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
3 Adrenergic alpha-Agonists Phase 4
4 Adrenergic Agents Phase 4
5 Analgesics, Non-Narcotic Phase 4
6 Hypnotics and Sedatives Phase 4
7 Analgesics Phase 4
8 Adrenergic Agonists Phase 4
9 Neurotransmitter Agents Phase 4
10 Fibrinolytic Agents Phase 4
11 calcium heparin Phase 4
12 Anticoagulants Phase 4
13
tannic acid Approved Phase 2, Phase 3 1401-55-4
14
Benzocaine Approved, Investigational Phase 2, Phase 3 94-09-7, 1994-09-7 2337
15
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
16
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
17
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
18 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
19
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
20
Colchicine Approved Phase 3 64-86-8 2833 6167
21
Lopinavir Approved Phase 3 192725-17-0 92727
22
Ritonavir Approved, Investigational Phase 3 155213-67-5 392622
23
Nitazoxanide Approved, Investigational, Vet_approved Phase 3 55981-09-4 41684
24
Hydroxychloroquine Approved Phase 3 118-42-3 3652
25
Azithromycin Approved Phase 3 83905-01-5 447043 55185
26
Clarithromycin Approved Phase 3 81103-11-9 84029
27
Methylcobalamin Approved, Investigational Phase 3 13422-55-4
28
Hydroxocobalamin Approved Phase 3 13422-51-0 15589840 11953898
29
Isotretinoin Approved Phase 3 4759-48-2 5282379 5538
30
Oseltamivir Approved Phase 3 204255-11-8, 196618-13-0 65028
31
Chlorpromazine Approved, Investigational, Vet_approved Phase 3 50-53-3 2726
32
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
33
Mannitol Approved, Investigational Phase 2, Phase 3 69-65-8 6251 453
34
chloroquine Approved, Investigational, Vet_approved Phase 2, Phase 3 54-05-7 2719
35
Zinc Approved, Investigational Phase 3 7440-66-6 32051
36
Ribavirin Approved Phase 3 36791-04-5 37542
37
Ivermectin Approved, Investigational, Vet_approved Phase 3 70288-86-7 6474909
38
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
39
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
40
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 444795 5538
41
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
42
Cobalamin Experimental Phase 3 13408-78-1 6857388
43
Nafamostat Investigational Phase 2, Phase 3 81525-10-2
44 Methylprednisolone Acetate Phase 2, Phase 3
45 glucocorticoids Phase 2, Phase 3
46 Neuroprotective Agents Phase 2, Phase 3
47 Immunologic Factors Phase 3
48 Immunoglobulins Phase 3
49 Antibodies Phase 3
50 Immunoglobulins, Intravenous Phase 3

Interventional clinical trials:

(show top 50) (show all 125)
# Name Status NCT ID Phase Drugs
1 Effects of Different Concentrations of Dexmedetomidine on Basal Ganglia Neuronal Activity (Local Field Potentials) in Parkinson's Disease Unknown status NCT02982512 Phase 4 Dexmedetomidine
2 Prevention of Coronavirus Disease (COVID-19) Outbreaks by Prophylactic Treatment With Nitazoxanide Recruiting NCT04406246 Phase 4 Nitazoxanide 500Mg Oral Tablet
3 Treatment With Hydroxychloroquine vs Nitazoxanide + Hydroxychloroquine in Patients With COVID-19 With Risk Factors for Poor Outcome Recruiting NCT04341493 Phase 4 Nitazoxanide 500 MG;Hydroxychloroquine
4 Nebulized Heparin vs. Placebo for the Treatment of COVID-19 Induced Lung Injury Enrolling by invitation NCT04397510 Phase 4 Heparin;0.9% Sodium-chloride
5 MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b: a Multicenter, Placebo-controlled, Double-blind Randomized Trial Completed NCT02845843 Phase 2, Phase 3 Combination of Lopinavir /Ritonavir and Interferon beta-1b;Placebo
6 Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by COVID-19: a Prospective, Randomized Controlled Trial Completed NCT04244591 Phase 2, Phase 3 methylprednisolone therapy
7 Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh Recruiting NCT04402203 Phase 2, Phase 3 Favipiravir;Only Standard Treatment
8 Convalescent Plasma Therapy From Recovered Covid-19 Patients as Therapy for Hospitalized Patients With Covid-19 Recruiting NCT04342182 Phase 2, Phase 3
9 Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19 Recruiting NCT04394416 Phase 3 Imatinib;Placebo oral tablet
10 The ECLA PHRI COLCOVID Trial Recruiting NCT04328480 Phase 3 Colchicine
11 Efficacy and Safety of Hyperimmune Plasma Treatment in Patients With COVID-19 Severe Infection Recruiting NCT04385043 Phase 2, Phase 3 standard therapy
12 Efficacy and Safety of Convalescent Plasma vs Human Immunoglobulin for the Treatment of COVID-19 Pneumonia: A Randomized Controlled Trial Recruiting NCT04381858 Phase 3 Plasma from COVID-19 convalescent patient;Human immunoglobulin
13 Trial of Silymarin in Adults With COVID-19 Pneumonia Not yet recruiting NCT04394208 Phase 3 Silymarin;Placebo
14 Isotretinoin in Treatment of COVID-19 (Randomized) Not yet recruiting NCT04353180 Phase 3 Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment;Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment;Standard treatment
15 Repurposing of Chlorpromazine in Covid-19 Treatment Not yet recruiting NCT04366739 Phase 3 CHLORPROMAZINE (CPZ)
16 Effectiveness of Hydroxychloroquine in Covid-19 Patients: A Single Centred Single-blind RCT Study Not yet recruiting NCT04328272 Phase 3 Hydroxychloroquine 200 Mg Oral Tablet;Azithromycin 500Mg Oral Tablet
17 Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome in Referral Hospitals in Indonesia Not yet recruiting NCT04380935 Phase 2, Phase 3 Standard of care
18 Evaluation Of Efficacy Of COVID-19 Convalescent Plasma Versus Standard Plasma In The Early Care Of COVID-19 Patients Hospitalized Outside Intensive Care Units. Not yet recruiting NCT04372979 Phase 3 Transfusion of SARS-CoV-2 Convalescent Plasma.;Transfusion of standard Plasma.
19 Treatment Effect of Nafamostat Mesylate in Patients With COVID-19 Pneumonia: Open Labelled Randomized Controlled Clinical Trial Not yet recruiting NCT04418128 Phase 2, Phase 3 Nafamostat Mesylate
20 #StayHome: Efficacy of Early Hydroxychloroquine in Outpatients to Reduce Secondary Hospitalisation and Household Transmission of COVID-19 in Switzerland: A Double-blind, Randomised, Placebo-controlled Trial Not yet recruiting NCT04385264 Phase 2, Phase 3 Hydroxychloroquine;Mannitol
21 Chloroquine for Mild Symptomatic and Asymptomatic COVID-19 in A Two Staged, Multicenter, Open Label and Randomized Trial Not yet recruiting NCT04333628 Phase 2, Phase 3 chloroquine
22 Study of the P2Et Extract Obtained From Caesalpinia Spinosa in the Symptomatic Treatment of Subjects With COVID-19 at the Hospital Universitario San Ignacio, Colombia. Not yet recruiting NCT04410510 Phase 2, Phase 3 P2Et (Caesalpinia spinosa extract)
23 The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients Not yet recruiting NCT04365517 Phase 3 Sitagliptin
24 Effect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19: a Pilot Sequential Clinical Trial Not yet recruiting NCT04392427 Phase 3 Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :
25 Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope Not yet recruiting NCT04361318 Phase 2, Phase 3
26 Clinical Trial Evaluating Safety and Efficacy of Ivermectin and Nitazoxanide Combination as Adjuvant Therapy in COVID-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope Not yet recruiting NCT04360356 Phase 2, Phase 3
27 A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Mild and Moderate COVID-19. Suspended NCT04252664 Phase 3 Remdesivir;Remdesivir placebo
28 Adaptive, Randomized, Single-blind, Three-arm Parallel Controlled Clinical Trial of Yinhu Qingwen Decoction in the Treatment of Mild / Common CoVID-19 Suspended NCT04278963 Phase 2, Phase 3 YinHu QingWen Decoction;YinHu QingWen Decoction(low dose)
29 An Adaptive, Randomized, Double-blind, Parallel-controlled Clinical Trial of Yinhu Qingwen Granula for the Treatment of Severe CoVID-19 Suspended NCT04310865 Phase 2, Phase 3 Yinhu Qingwen Granula;Yin Hu Qing Wen Granula(low does)
30 A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe COVID-19. Terminated NCT04257656 Phase 3 Remdesivir;Remdesivir placebo
31 Phase I/IIa, Open-label, Dose Ranging Study to Evaluate the Safety, Tolerability and Immunogenicity of GLS-5300, Administered ID Followed by CELLECTRA® 2000 (Electroporation, EP) Completed NCT03721718 Phase 1, Phase 2
32 Using Systems Vaccinology to Elucidate the Effects of Anti-inflammatory Therapy on Immune Response After Vaccination With a Live Attenuated Vaccine Completed NCT03116802 Phase 2 Stamaril (live attenuated yellow fever vaccine)
33 Double-blind, Placebo-controlled Study With an Open Dose Selection Period for Assessing the Safety and Immunogenicity of the Drug "BVRS-GamVac", a Vector Vaccine for the Prevention of the Middle East Respiratory Syndrome, Lyophilisate for the Preparation of a Solution for Intramuscular Administration, With the Participation of Healthy Volunteers Recruiting NCT04130594 Phase 1, Phase 2
34 Double-blind, Placebo-controlled Study With an Open Dose Selection Period for Assessing the Safety and Immunogenicity of the Drug "BVRS-GamVac-Combi", a Combined Vector Vaccine for the Prevention of the Middle East Respiratory Syndrome, Lyophilisate for the Preparation of a Solution for Intramuscular Administration, With the Participation of Healthy Volunteers Recruiting NCT04128059 Phase 1, Phase 2 BVRS-GamVac-Combi
35 A Phase 2, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Convalescent Plasma in Severely Ill Adults With COVID-19 Recruiting NCT04359810 Phase 2
36 A Phase 2 Randomized, Double-blinded Trial to Evaluate the Efficacy and Safety of Human Anti- SARS-CoV-2 Plasma in Close Contacts of COVID-19 Cases Recruiting NCT04390503 Phase 2
37 A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19 Recruiting NCT04347681 Phase 2
38 Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients With Severe SARS-CoV-2 Pneumonia: An Open-Label, Multicenter Sequential and Cluster Randomized Trial Recruiting NCT04322773 Phase 2 RoActemra iv;RoActemra sc;Kevzara sc
39 Plasma From Covalescent Donors With Covid-19 for the Management of Patients With SARS-COV-2 Fase II and III, a Doble Center Randomized Doble Blind Trial Recruiting NCT04405310 Phase 2
40 Convalescent Plasma Transfusion Therapy in Severe COVID-19 Patients- a Tolerability, Efficacy and Dose-response Phase II RCT Recruiting NCT04403477 Phase 2
41 Transfusion of Convalescent Plasma for the Early Treatment of pneumonIa Due to SARSCoV2: a Multicenter Open Label Randomized Control Trial Recruiting NCT04393727 Phase 2
42 Efficacy and Safety of Early Anti-SARS-COV-2 Convalescent Plasma in Patients Admitted for COVID-19 Infection: a Randomized Phase II Trial Recruiting NCT04375098 Phase 2
43 Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers Recruiting NCT04347954 Phase 1, Phase 2 Povidone-Iodine 2%;Povidone-Iodine 0.5%;Isotonic saline 0.9%
44 An Open-label Randomized Controlled Trial on Interferon β-1b and Hydroxychloroquine Combination Versus Hydroxychloroquine Alone, as Treatment for COVID-19 Infection Recruiting NCT04350281 Phase 2 Interferon Beta-1B;Hydroxychloroquine
45 Colchicine to Counteract Inflammatory Response in COVID-19 Pneumonia Recruiting NCT04322565 Phase 2 Colchicine
46 Randomized Phase II Clinical Trial of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.Ruxo-Sim-20 Clinical Trial. Recruiting NCT04348695 Phase 2 Ruxolitinib plus simvastatin
47 A Phase 2 Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection Recruiting NCT04392232 Phase 2 Convalescent Plasma
48 A Randomised Double-blind Placebo-controlled Trial to Determine the Safety and Efficacy of Inhaled SNG001 (IFN-β1a for Nebulisation) for the Treatment of Patients With Confirmed SARS-CoV-2 Infection Recruiting NCT04385095 Phase 2 Interferon beta 1a;Placebo
49 Povidone-Iodine Intranasal for Prophylaxis in Front-line Health-care Personnel and Inpatients During the Sars-CoV-2 Pandemic Recruiting NCT04364802 Phase 2 Povidone-Iodine Nasal Spray and Gargle;Povidone-Iodine Nasal Spray and Gargle
50 Prospective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Hydroxychloroquine Together With Baricitinib, Imatinib or Early Lopinavir / Ritonavir in Patients With SARS Cov2 Pneumonia Recruiting NCT04346147 Phase 2 Hidroxicloroquine;Lopinavir/ritonavir;Imatinib tablets;Baricitinib Oral Tablet

Search NIH Clinical Center for Middle East Respiratory Syndrome

Genetic Tests for Middle East Respiratory Syndrome

Anatomical Context for Middle East Respiratory Syndrome

MalaCards organs/tissues related to Middle East Respiratory Syndrome:

40
T Cells, Testes, Brain, Lung, Kidney, B Cells, Subthalamic Nucleus

Publications for Middle East Respiratory Syndrome

Articles related to Middle East Respiratory Syndrome:

(show top 50) (show all 4965)
# Title Authors PMID Year
1
Competing endogenous RNA network profiling reveals novel host dependency factors required for MERS-CoV propagation. 61
32223537 2020
2
COVID-19: animals, veterinary and zoonotic links. 61
32393111 2020
3
Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity. 61
32403995 2020
4
Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. 61
32196410 2020
5
Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2. 61
32306853 2020
6
Inhibition of SARS-CoV 3CL protease by flavonoids. 61
31724441 2020
7
Emergency nurses' perceptions regarding the risks appraisal of the threat of the emerging infectious disease situation in emergency departments. 61
31975652 2020
8
Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments. 61
32036774 2020
9
Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV. 61
32471334 2020
10
Animal models for emerging coronavirus: progress and new insights. 61
32378471 2020
11
COVID-19: Development of a robust mathematical model and simulation package with consideration for ageing population and time delay for control action and resusceptibility. 61
32536738 2020
12
Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. 61
32320825 2020
13
Structure and dynamics of phospholipids in membranes elucidated by combined use of NMR and vibrational spectroscopies. 61
32407775 2020
14
Epidemiological changes of acute encephalopathy in Japan based on national surveillance for 2014-2017. 61
32360071 2020
15
Coronaviruses pathogenesis, comorbidities and multi-organ damage - A review. 61
32450165 2020
16
Mathematical model of infection kinetics and its analysis for COVID-19, SARS and MERS. 61
32278147 2020
17
Possible environmental effects on the spread of COVID-19 in China. 61
32402910 2020
18
Coronaviruses pandemics: Can neutralizing antibodies help? 61
32450171 2020
19
Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 Mpro enzyme through in silico approach. 61
32450166 2020
20
What are the main patient safety concerns of healthcare stakeholders: a mixed-method study of Web-based text. 61
32416430 2020
21
Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus. 61
32203126 2020
22
Built-in RNA-mediated chaperone (chaperna) for antigen folding tailored to immunized hosts. 61
32297972 2020
23
Coronavirus in water environments: Occurrence, persistence and concentration methods - A scoping review. 61
32361598 2020
24
Natural product-derived phytochemicals as potential agents against coronaviruses: A review. 61
32360300 2020
25
Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. 61
32222463 2020
26
The diagnosis of pandemic coronavirus pneumonia: A review of radiology examination and laboratory test. 61
32438256 2020
27
The emergence of SARS, MERS and novel SARS-2 coronaviruses in the 21st century. 61
32322993 2020
28
Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis. 61
32360583 2020
29
Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease. 61
32361744 2020
30
[Comment] Treatment strategies to fight the new coronavirus SARS-CoV-2: A challenge for a Rubik's Cube solver. 61
32536988 2020
31
Reconfiguring the scope and practice of regional anesthesia in a pandemic: the COVID-19 perspective. 61
32471930 2020
32
Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. 61
32227493 2020
33
Current epidemiological and clinical features of COVID-19; a global perspective from China. 61
32315723 2020
34
Assessment of the quality of systematic reviews on COVID-19: A comparative study of previous coronavirus outbreaks. 61
32301508 2020
35
The emergence of a novel coronavirus (SARS-CoV-2) disease and their neuroinvasive propensity may affect in COVID-19 patients. 61
32320066 2020
36
Shell disorder analysis predicts greater resilience of the SARS-CoV-2 (COVID-19) outside the body and in body fluids. 61
32244041 2020
37
Sixty-eight consecutive patients assessed for COVID-19 infection: Experience from a UK Regional infectious diseases Unit. 61
32223012 2020
38
Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? 61
32291137 2020
39
Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. 61
32506195 2020
40
Epidemiological analysis of COVID-19 and practical experience from China. 61
32237160 2020
41
Clinical Insights into the Gastrointestinal Manifestations of COVID-19. 61
32447742 2020
42
COVID-19, SARS and MERS: A neurological perspective. 61
32417124 2020
43
COVID-19: A promising cure for the global panic. 61
32278175 2020
44
COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. 61
32257431 2020
45
Myocardial injury and COVID-19: Possible mechanisms. 61
32360126 2020
46
Current targeted therapeutics against COVID-19: Based on first-line experience in China. 61
32360585 2020
47
Advances in the relationship between coronavirus infection and cardiovascular diseases. 61
32428835 2020
48
The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. 61
32283144 2020
49
The Role of Human Coronavirus Infection in Pediatric Acute Gastroenteritis. 61
32433226 2020
50
Surveillance and Testing for Middle East Respiratory Syndrome Coronavirus, Saudi Arabia, March 2016-March 2019. 61
32568049 2020

Variations for Middle East Respiratory Syndrome

Expression for Middle East Respiratory Syndrome

Search GEO for disease gene expression data for Middle East Respiratory Syndrome.

Pathways for Middle East Respiratory Syndrome

Pathways related to Middle East Respiratory Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.14 IRF3 IFIH1 CXCL10 CEACAM5
2
Show member pathways
12.06 IRF3 IFNB1 IFIH1 CXCL10
3
Show member pathways
12.05 ISG15 IRF3 IFNB1 IFIH1 CXCL10
4
Show member pathways
11.81 TMPRSS2 ISG15 IRF3 IFNB1 IFIH1 CXCL10
5 10.7 ISG15 IFNB1 CXCL10

GO Terms for Middle East Respiratory Syndrome

Cellular components related to Middle East Respiratory Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.76 TMPRSS2 PPP1CA HSPA5 FURIN DPP4 CTSL
2 extracellular region GO:0005576 9.61 TMPRSS2 ISG15 IFNB1 FURIN DPP4 CXCL10
3 cell surface GO:0009986 9.1 HSPA5 FURIN DPP4 CEACAM5 ADA ACE2

Biological processes related to Middle East Respiratory Syndrome according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 proteolysis GO:0006508 9.89 TMPRSS2 FURIN DPP4 CTSL ACE2
2 response to bacterium GO:0009617 9.69 ISG15 IRF3 CXCL10
3 type I interferon signaling pathway GO:0060337 9.63 ISG15 IRF3 IFNB1
4 response to virus GO:0009615 9.62 PRKRA IFNB1 IFIH1 CXCL10
5 defense response to virus GO:0051607 9.55 ISG15 IRF3 IFNB1 IFIH1 CXCL10
6 negative regulation of type I interferon production GO:0032480 9.54 ISG15 IRF3 IFIH1
7 positive regulation of interferon-alpha production GO:0032727 9.48 IRF3 IFIH1
8 MDA-5 signaling pathway GO:0039530 9.43 IRF3 IFIH1
9 regulation of cell-cell adhesion mediated by integrin GO:0033632 9.4 DPP4 ADA
10 macrophage apoptotic process GO:0071888 9.26 IRF3 CTSL
11 viral process GO:0016032 9.17 PRKRA PPP1CA ISG15 IRF3 IFIH1 FURIN
12 cellular response to exogenous dsRNA GO:0071360 9.13 IRF3 IFNB1 IFIH1

Molecular functions related to Middle East Respiratory Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.19 TMPRSS2 SCARA3 PRKRA PPP1CA ISG15 IRF3
2 peptidase activity GO:0008233 9.35 TMPRSS2 FURIN DPP4 CTSL ACE2
3 hydrolase activity GO:0016787 9.28 TMPRSS2 PPP1CA IFIH1 HSPA5 FURIN DPP4
4 dipeptidyl-peptidase activity GO:0008239 9.16 DPP4 ACE2

Sources for Middle East Respiratory Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....